BGI Genomics(300676)2024-10-25 12:15Financial Performance - Revenue for the third quarter was RMB 954.49 million, a decrease of 10.93% year-over-year[2] - Net profit attributable to shareholders of the listed company was RMB -142.37 million, a decrease of 792.32% year-over-year[2] - Revenue for the first three quarters of 2024 was 2.825 billion yuan, a decrease of 10.10% year-over-year[12] - Net profit attributable to shareholders for the first three quarters of 2024 was -124.1661 million yuan, a decrease of 276.49% year-over-year[12] - Revenue for the third quarter of 2024 was 954.4853 million yuan, a decrease of 10.93% year-over-year[12] - Net profit attributable to shareholders for the third quarter of 2024 was -142.3659 million yuan, a decrease of 792.32% year-over-year[12] - Gross margin decreased by 3.07% year-over-year due to the "low-price benefit" strategy and product structure adjustments[12] - Total operating revenue for the current period was 2,825,935,926.99, a decrease from the previous period's 3,143,452,163.96[21] - Operating costs for the current period were 1,548,174,697.10, down from 1,625,482,961.92 in the previous period[21] - Net profit for the current period was -124,180,426.78, a significant decline from 70,146,749.72 in the previous period[22] Cash Flow - The company's operating cash flow for the period was RMB -142.81 million, a decrease of 178.41% year-over-year[2] - Investment cash flow for the period was RMB -527.08 million, a decrease of 608.58% year-over-year[6] - Net cash flow from operating activities was -142.81 million yuan, compared to 182.13 million yuan in the previous period[25] - Net cash flow from investing activities was -527.08 million yuan, compared to -74.39 million yuan in the previous period[25] - Net cash flow from financing activities was -316.81 million yuan, compared to -213.99 million yuan in the previous period[25] - Total cash inflow from investing activities was 7.66 billion yuan, compared to 2.80 billion yuan in the previous period[25] - Total cash outflow from investing activities was 8.19 billion yuan, compared to 2.87 billion yuan in the previous period[25] - Cash and cash equivalents at the end of the period were 2.59 billion yuan, compared to 5.10 billion yuan in the previous period[25] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets was 364.14 million yuan, compared to 945.82 million yuan in the previous period[25] - Cash outflow for investments was 7.82 billion yuan, compared to 1.92 billion yuan in the previous period[25] - Cash inflow from investment returns was 76.46 million yuan, compared to 230.41 million yuan in the previous period[25] - Cash outflow for debt repayment was 22.79 million yuan, compared to 6.00 million yuan in the previous period[25] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 13.28 billion, a decrease of 2.41% compared to the end of the previous year[2] - The company's long-term loans increased by 61.14% to RMB 347.54 million[6] - The company's monetary funds decreased from RMB 4,732,376,385.95 at the beginning of the period to RMB 3,779,410,999.45 at the end of the period[18] - The company's accounts receivable increased from RMB 1,443,946,645.90 at the beginning of the period to RMB 1,829,117,714.81 at the end of the period[18] - The company's total assets decreased from RMB 13,613,007,886.01 at the beginning of the period to RMB 13,284,380,251.44 at the end of the period[19] - The company's total liabilities decreased from RMB 3,608,987,599.21 at the beginning of the period to RMB 3,313,098,459.67 at the end of the period[20] - The company's total equity decreased slightly from RMB 10,004,020,286.80 at the beginning of the period to RMB 9,971,281,791.77 at the end of the period[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 65,696[7] - Shenzhen Huada Gene Technology Co., Ltd. holds 35.78% of the shares, totaling 148,773,893 shares[7] - Shenzhen Shenghua Investment Enterprise (Limited Partnership) holds 8.29% of the shares, totaling 34,470,455 shares[7] - China Merchants Bank Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 2.16% of the shares, totaling 9,000,038 shares[7] - Bank of China Limited - Huabao CSI Medical ETF holds 2.00% of the shares, totaling 8,334,173 shares[7] - Industrial and Commercial Bank of China Limited - E Fund ChiNext ETF holds 1.59% of the shares, totaling 6,603,143 shares[8] - Agricultural Bank of China Limited - CSI 500 ETF holds 1.12% of the shares, totaling 4,660,700 shares[8] - Shenzhen Huada Sanshengyuan Technology Co., Ltd. holds 0.95% of the shares, totaling 3,935,824 shares[8] - Shenzhen Huada Gene Co., Ltd. - Second Phase Employee Stock Ownership Plan holds 0.88% of the shares, totaling 3,679,441 shares[8] - Hong Kong Securities Clearing Company Limited holds 0.82% of the shares, totaling 3,411,574 shares[8] Business Segments - Reproductive health business revenue for the first three quarters of 2024 was nearly 900 million yuan, an increase of 3.7% year-over-year[13] - Tumor and chronic disease prevention business revenue for the first three quarters of 2024 was nearly 400 million yuan, an increase of 14.1% year-over-year[13] - Infection prevention and control business revenue for the first three quarters of 2024 was 53 million yuan, a decrease of 85.4% year-over-year[13] Expenses and Losses - Credit impairment losses increased by 567.63% to RMB -105.49 million[6] - The company's financial expenses decreased by 141.59% to RMB -59.12 million[6] - The company's investment income decreased by 171.72% to RMB -21.85 million[6] - The company's income tax expense decreased by 117.03% to RMB -2.84 million[6] - Credit impairment losses increased by 89.69 million yuan year-over-year due to slower accounts receivable collection[12] - Investment losses from equity method investments increased by 39.51 million yuan year-over-year[12] - R&D expenses increased to 398,014,771.10 from 388,313,454.65 in the previous period[22] - Taxes and surcharges increased to 12,759,204.55 from 7,685,898.04 in the previous period[21] - Sales expenses decreased to 663,331,251.16 from 757,102,622.30 in the previous period[21] Investments and Shareholdings - The company's directors and senior executives have cumulatively increased their shareholdings by 144,400 shares, accounting for 0.0347% of the total shares, with a total investment of RMB 5,098,552, which is more than half of the planned RMB 10 million[16] - The company invested RMB 149 million to participate in the subscription of Shaoxing Meiyue Medical Industry Equity Investment Partnership (Limited Partnership) fund, targeting the life and health sector with a planned fundraising scale of RMB 500 million[17] Operating Activities - Cash received from sales of goods and services was 2,312,310,695.98, down from 3,584,309,809.63 in the previous period[24] - Total cash inflows from operating activities were 2,541,858,433.66, compared to 3,784,255,101.26 in the previous period[24] - Cash paid for goods and services was 1,057,292,663.53, a decrease from 1,515,900,082.58 in the previous period[24] - Cash paid to employees and for employee benefits was 925,531,974.13, down from 1,050,773,258.03 in the previous period[24]